Figure S7 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells | Synapse
August 2, 2025
Figure S7 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Key Points
MAIN FINDING: IGM-7354 significantly enhances cytotoxicity against PD-L1-positive MDA-MB-231 tumor cells.
KEY EVIDENCE: The immunocytokine promotes the activation of NK and CD8+ T cells to effectively kill tumor cells.
APPROACH: The research involved in vitro assays to measure the impact of IGM-7354 on immune cell functionality.
SIGNIFICANCE: This work highlights a new potential therapeutic strategy for targeting cancer cells using immune modulation.
Abstract
Supplemental Figure 7. IGM-7354 promotes the killing of MDA-MB-231 tumor cells in vitro and preferentially modulates CD8+ T cells.